171 related articles for article (PubMed ID: 23011911)
1. Prognostic factors for recurrence and survival in anal cancer: generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I).
Glynne-Jones R; Sebag-Montefiore D; Adams R; Gollins S; Harrison M; Meadows HM; Jitlal M;
Cancer; 2013 Feb; 119(4):748-55. PubMed ID: 23011911
[TBL] [Abstract][Full Text] [Related]
2. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.
Gunderson LL; Winter KA; Ajani JA; Pedersen JE; Moughan J; Benson AB; Thomas CR; Mayer RJ; Haddock MG; Rich TA; Willett CG
J Clin Oncol; 2012 Dec; 30(35):4344-51. PubMed ID: 23150707
[TBL] [Abstract][Full Text] [Related]
3. Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial.
Gunderson LL; Moughan J; Ajani JA; Pedersen JE; Winter KA; Benson AB; Thomas CR; Mayer RJ; Haddock MG; Rich TA; Willett CG
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):638-45. PubMed ID: 24035327
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205).
Garg MK; Zhao F; Sparano JA; Palefsky J; Whittington R; Mitchell EP; Mulcahy MF; Armstrong KI; Nabbout NH; Kalnicki S; El-Rayes BF; Onitilo AA; Moriarty DJ; Fitzgerald TJ; Benson AB
J Clin Oncol; 2017 Mar; 35(7):718-726. PubMed ID: 28068178
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08.
Konski A; Garcia M; John M; Krieg R; Pinover W; Myerson R; Willett C
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):114-8. PubMed ID: 18472363
[TBL] [Abstract][Full Text] [Related]
6. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.
Ajani JA; Winter KA; Gunderson LL; Pedersen J; Benson AB; Thomas CR; Mayer RJ; Haddock MG; Rich TA; Willett C
JAMA; 2008 Apr; 299(16):1914-21. PubMed ID: 18430910
[TBL] [Abstract][Full Text] [Related]
7. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
James RD; Glynne-Jones R; Meadows HM; Cunningham D; Myint AS; Saunders MP; Maughan T; McDonald A; Essapen S; Leslie M; Falk S; Wilson C; Gollins S; Begum R; Ledermann J; Kadalayil L; Sebag-Montefiore D
Lancet Oncol; 2013 May; 14(6):516-24. PubMed ID: 23578724
[TBL] [Abstract][Full Text] [Related]
8. A population-based analysis of the impact of 1 vs. 2 doses of mitomycin on patterns of failure of anal cancer patients treated with concurrent chemoradiotherapy.
Joseph K; Al Habsi Z; Abraham A; Elangovan A; Ghosh S; Pham T; Shreekumar D; Ramji Z; Paulson K; Tankel K; Usmani N; Severin D; Schiller D; Wong C; Mulder K; Karachiwala H; Doll C; King K; Nijjar T
Radiother Oncol; 2024 Jul; 196():110219. PubMed ID: 38479443
[TBL] [Abstract][Full Text] [Related]
9. The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer.
Franco P; Montagnani F; Arcadipane F; Casadei C; Andrikou K; Martini S; Iorio GC; Scartozzi M; Mistrangelo M; Fornaro L; Cassoni P; Cascinu S; Ricardi U; Casadei Gardini A
Radiat Oncol; 2018 May; 13(1):83. PubMed ID: 29720197
[TBL] [Abstract][Full Text] [Related]
10. Sarcopenia and dosimetric parameters in relation to treatment-related leukopenia and survival in anal cancer.
Nilsson MP; Johnsson A; Scherman J
Radiat Oncol; 2021 Aug; 16(1):152. PubMed ID: 34399812
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of p53 protein and outcome of patients treated with chemoradiation for carcinoma of the anal canal: a report of randomized trial RTOG 87-04. Radiation Therapy Oncology Group.
Bonin SR; Pajak TF; Russell AH; Coia LR; Paris KJ; Flam MS; Sauter ER
Cancer; 1999 Mar; 85(6):1226-33. PubMed ID: 10189126
[TBL] [Abstract][Full Text] [Related]
12. Definitive chemoradiotherapy for anal canal cancer: single-center experience.
Tachibana I; Nishimura Y; Inada M; Fukuda K; Ishikawa K; Nishikawa T; Yokokawa M; Nakamatsu K; Kanamori S; Hida JI
Int J Clin Oncol; 2018 Dec; 23(6):1121-1126. PubMed ID: 29992389
[TBL] [Abstract][Full Text] [Related]
13. Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning.
Wright JL; Patil SM; Temple LK; Minsky BD; Saltz LB; Goodman KA
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1064-72. PubMed ID: 20350793
[TBL] [Abstract][Full Text] [Related]
14. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research.
Lancet; 1996 Oct; 348(9034):1049-54. PubMed ID: 8874455
[TBL] [Abstract][Full Text] [Related]
15. Chemoradiotherapy for squamous cell anal carcinoma: a review of prognostic factors.
Kapacee ZA; Susnerwala S; Wise M; Biswas A; Danwata F; Scott N
Colorectal Dis; 2016 Nov; 18(11):1080-1086. PubMed ID: 27028038
[TBL] [Abstract][Full Text] [Related]
16. Significance of Co-expression of Epidermal Growth Factor Receptor and Ki67 on Clinical Outcome in Patients With Anal Cancer Treated With Chemoradiotherapy: An Analysis of NRG Oncology RTOG 9811.
Doll CM; Moughan J; Klimowicz A; Ho CK; Kornaga EN; Lees-Miller SP; Ajani JA; Crane CH; Kachnic LA; Okawara GS; Berk LB; Roof KS; Becker MJ; Grisell DL; Ellis RJ; Sperduto PW; Marsa GW; Guha C; Magliocco AM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):554-562. PubMed ID: 28126304
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index.
Hung A; Crane C; Delclos M; Ballo M; Ajani J; Lin E; Feig B; Skibber J; Janjan N
Cancer; 2003 Mar; 97(5):1195-202. PubMed ID: 12599225
[TBL] [Abstract][Full Text] [Related]
18. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I).
Northover J; Glynne-Jones R; Sebag-Montefiore D; James R; Meadows H; Wan S; Jitlal M; Ledermann J
Br J Cancer; 2010 Mar; 102(7):1123-8. PubMed ID: 20354531
[TBL] [Abstract][Full Text] [Related]
19. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups.
Bartelink H; Roelofsen F; Eschwege F; Rougier P; Bosset JF; Gonzalez DG; Peiffert D; van Glabbeke M; Pierart M
J Clin Oncol; 1997 May; 15(5):2040-9. PubMed ID: 9164216
[TBL] [Abstract][Full Text] [Related]
20. "Mind the gap"--the impact of variations in the duration of the treatment gap and overall treatment time in the first UK Anal Cancer Trial (ACT I).
Glynne-Jones R; Sebag-Montefiore D; Adams R; McDonald A; Gollins S; James R; Northover JM; Meadows HM; Jitlal M;
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1488-94. PubMed ID: 20934265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
